Browsing Tag
Gilgamesh Pharmaceuticals
5 posts
Is bretisilocin the Cymbalta of psychedelic‑inspired psychiatry? What AbbVie’s $1.2 bn bet reveals
AbbVie’s $1.2 B deal for bretisilocin could signal the next era of antidepressants. Could this short‑acting compound become the Cymbalta of psychedelic‑inspired psychiatry?
AbbVie completes $1.2bn acquisition of Gilgamesh’s bretisilocin: Is big pharma finally embracing psychedelic psychiatry?
AbbVie completes $1.2B acquisition of bretisilocin from Gilgamesh, betting big on short-acting psychiatric drugs. Here’s what the deal signals for depression care.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.
Can short-acting psychedelics solve the scalability problem in depression treatment?
Short-acting psychedelics like bretisilocin could reshape mental health treatment. Can they overcome the clinical bottlenecks faced by psilocybin and ketamine?
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.